9 Meters Biopharma (NMTR) Peer Comparison
$0.02
$0.00
(2.05%)
As on 26-Sep-2023 09:30EDT
Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Edit
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1 | 16,504 | 14,622 | 12,506 | 12,501 |
Revenue ($ Mln) |
-- | 2,782 | 2,436 | 1,664 | 1,284 |
Net Profit ($ Mln) |
-49.80 | 491.50 | 860.62 | 413.60 | -325.10 |
Net Margin (%) |
-- | 17.67 | 35.33 | 24.86 | -25.32 |
RoE (%) |
-- | 110.09 | 42.98 | 430.03 | -57.72 |
Price to Earnings |
-- | 34.72 | 18.56 | 32.31 | -- |
Price-To-Book |
1.59 | 38.18 | 7.95 | 86.71 | 23.94 |
Income Statement ($ Mln)
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 1,460.00 | 1,611.06 | 660.12 | 0.00 |
|
Cost of Revenue
|
0.00 | 1,027.56 | 57.91 | 139.30 | 0.47 |
|
Gross Profit
|
-- | 432.44 | 1,553.15 | 520.81 | 0.00 |
|
Operating Expenses
|
43.44 | 153.74 | 1,351.67 | 253.28 | 293.57 |
|
Operating Profit (EBIT)
|
-43.44 | 278.70 | 201.48 | 267.53 | -293.57 |
|
Other Income
|
0.00 | 7.07 | -0.20 | -1.67 | 2.19 |
|
Profit before Tax
|
-46.28 | 282.86 | 234.35 | 248.92 | -295.35 |
|
Provision for Tax
|
3.52 | 37.49 | 52.07 | 46.79 | 3.96 |
|
Profit after Tax (Net Income)
|
-49.80 | 245.37 | 182.28 | 202.13 | -295.35 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-20.48 | 245.37 | 182.28 | 202.13 | -295.35 |
Liabilities ($ Mln)
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-6.30 | 386.39 | 2,488.43 | 169.80 | 197.39 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.03 | 162.64 | 258.70 | 1,540.92 | 49.29 |
|
Current Liabilities
|
15.58 | 803.47 | 324.36 | 130.79 | 115.89 |
|
Total Liabilities
|
33.15 | 1,352.50 | 3,071.49 | 1,841.51 | 362.57 |
Assets ($ Mln)
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.12 | 1,018.53 | 1,452.73 | 1,102.50 | 1.20 |
|
Current Assets
|
9.20 | 333.96 | 1,618.76 | 739.01 | 361.37 |
|
Total Assets
|
33.15 | 1,352.50 | 3,071.49 | 1,841.51 | 362.57 |
|
Total Debt*
|
5.17 | 188.87 | 190.17 | 1,506.10 | 49.89 |
|
Net Current Assets
|
-6.38 | -469.51 | 1,294.40 | 608.22 | 245.48 |
Cashflow ($ Mln)
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-37.24 | 388.05 | 362.61 | 240.11 | -224.86 |
|
Cash Flow from Investing Activities
|
-- | -38.74 | -524.41 | -487.01 | 206.69 |
|
Cash from Financing Activities
|
19.91 | -775.78 | 0.59 | 362.37 | 313.45 |
|
Net Cash Inflow / Outflow
|
-- | -426.47 | -161.21 | 115.48 | 295.28 |
Ratios
Profitability Ratios
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-142.46 | 29.58 | 7.38 | 14.70 | -132.99 |
|
ROE (%)
|
-206.87 | 36.64 | 7.76 | 110.23 | -150.12 |
|
ROA (%)
|
-137.61 | 16.29 | 6.41 | 13.72 | -92.89 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 16.73 | 11.32 | 30.70 | -13,517.16 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.28 | 0.12 | 0.49 | -- |
|
EBIT Growth (%)
|
-15.52 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-16.66 | 34.93 | -21.11 | -49.81 | -22.51 |
|
EPS Growth (%)
|
-- | 0.57 | -0.21 | -0.48 | -0.21 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 28.07 | 28.45 | 39.02 | -16.94 |
|
Price / Book Value
|
-- | 17.82 | 2.08 | 46.45 | 25.35 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.17 | 22.87 | 18.29 | 28.62 | -16.14 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.49 | 0.08 | 8.87 | 0.25 |
|
Short term debt to equity ratio
|
-0.82 | 0.13 | 0.01 | 0.08 | 0.00 |
|
Current Ratio
|
0.59 | 0.42 | 4.99 | 5.65 | 3.12 |
|
Quick Ratio
|
0.59 | -- | 4.89 | 4.88 | -- |
|
Interest Coverage
|
-12.28 | 98.37 | 3.75 | 15.69 | -73.51 |
Operating Efficiency Ratios
| 9 Meters Biopharma (NMTR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 17.36 | 13.33 | 35.00 | -- |
|
Asset Turnover
|
0.00 | 0.97 | 0.57 | 0.45 | 0.00 |
|
Receivable days
|
-- | 55.02 | 56.39 | 89.10 | -- |
|
Inventory Days
|
-- | -- | 191.72 | 201.93 | -- |
|
Payable days
|
-- | 10.44 | 179.52 | 25.22 | 17,680.21 |
|
Cash Conversion Cycle
|
-- | -- | 68.58 | 265.81 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
